FDA Approvals Daraxonrasib for Pancreatic Cancer, Doubling Survival in Landmark Move

A Long-Looked-for Breakthrough in Pancreatic Cancer

The FDA has approved daraxonrasib, branded as Rasonque, becoming the first drug to successfully target KRAS mutations in pancreatic cancer — a milestone reached decades after researchers first identified the genetic driver behind more than 90 percent of these deadly tumors. Revolutionary Medicines, the Redwood City-based company behind the drug, received expedited approval Wednesday, clearing a regulatory pathway designed to fast-track treatments for serious conditions.

The approval arrives over six months ahead of the FDA’s target date. Acting Commissioner Kyle Diamantas called it a fulfillment of the agency’s fundamental duty to deliver meaningful treatments as quickly as possible.

For patients who have waited lifetimes for progress against a disease with a five-year survival rate of just 13 percent, the news carried immediate weight. The announcement sent waves of relief through oncology clinics nationwide, where physicians had grown accustomed to delivering sobering prognosis without viable next-line options.

How Much Time Does It Add?

In the pivotal trial, 500 patients with metastatic pancreatic cancer whose tumors had stopped responding to prior treatment were randomly assigned to receive either daraxonrasib or more chemotherapy. The results were stark.

Patients on daraxonrasib lived a median of 13.2 months compared with 6.7 months on chemotherapy. That is nearly a doubling of survival time — not a cure, but a dramatic extension of life for a disease that has offered patients very little in recent decades.

Side effects were manageable: skin rash, mouth sores, diarrhea, and other digestive issues. No new safety signals emerged that would have complicated the approval decision.

The Kaplan-Meier survival curves from the trial showed a persistent separation between the two arms, with daraxonrasib patients maintaining a meaningful advantage throughout the follow-up period. This durability of effect was considered particularly significant given the aggressive nature of metastatic pancreatic cancer and the rapid progression typically seen after standard therapies fail.

Why KRAS Was So Hard to Crack

The KRAS gene family regulates cell growth. When mutated, it becomes locked in an always-on state, driving uncontrolled tumor proliferation. For years, the protein’s smooth, featureless surface gave drugmakers nothing to grab onto. It was deemed undruggable.

Daraxonrasib solves this problem using what Revolution Medicines describes as a molecular glue approach. Rather than fitting into a traditional binding pocket, the drug brings together two proteins — the mutated KRAS and an E3 ubiquitin ligase — causing the cell’s own degradation machinery to tag the oncogenic protein for destruction. This mechanism allows it to bind multiple KRAS subtypes simultaneously, which explains its broad activity across pancreatic, lung, and potentially other KRAS-driven cancers.

The same technology platform is now under investigation in lung cancer and several other tumor types. If the approach proves safe and effective across indications, it could establish molecular gluing as a mainstream drug discovery strategy.

This paradigm shift — from blocking protein function to promoting protein degradation — represents one of the most significant conceptual advances in oncology drug development in over a decade. Traditional small molecule inhibitors work by occupying a binding site and preventing the protein from functioning. Molecular glues, by contrast, hijack the cell’s waste disposal system, forcing the unwanted protein to be destroyed entirely. This approach can target proteins previously considered “undruggable” simply because they lack suitable binding pockets.

What This Means for Patients

Not every patient qualifies. The drug targets the subset of pancreatic cancers harboring KRAS mutations — which, based on the source data, encompasses more than 90 percent of cases. That leaves a small percentage of patients without a directly applicable targeted option, though they may still benefit from conventional chemotherapy.

The trial enrolled patients whose cancer had already progressed on prior treatment. In clinical practice, that means daraxonrasib is positioned as a second-line or later therapy, not a first-line intervention. Dr. Pashtoon Kasi of City of Hope Orange County framed it plainly: “This is not a cure. It’s one more option for these patients. But it’s the best option we’ve ever had.”

Still, for a disease where median survival after progression has hovered around six months for years, adding another six is a meaningful gain. For patients and families who have watched pancreatic cancer consume loved ones with brutal efficiency, any extension of life carries profound importance.

The practical implications for oncologists will be significant. Tumor genomic testing, which has become standard of care in metastatic pancreatic cancer, will now yield actionable results for the vast majority of patients — a dramatic contrast to the current landscape where even comprehensive molecular profiling often returns no therapeutic recommendations.

The Public Eye Was Already on This Drug

Daraxonrasib gained attention earlier this year when former Sen. Ben Sasse, a Republican from Nebraska, appeared on CBS’s “60 Minutes” describing reduced pain while taking the experimental treatment. His public testimony triggered a surge in patient interest that led the FDA to grant expanded access — allowing doctors to prescribe the drug before formal approval to patients meeting certain criteria.

That expanded access program demonstrated real-world effectiveness ahead of the regulatory decision and likely strengthened the case for approval. Throughout the pre-approval period, oncology practices reported managing increased inquiries from patients desperate for access to the experimental therapy.

The expanded access framework, sometimes called compassionate use, allowed approximately 800 additional patients to receive daraxonrasib before the formal approval decision. Early data from these patients suggested response rates and toxicity profiles consistent with the pivotal trial, providing real-world confidence in the drug’s benefit-risk profile.

The Ripple Effect Across Oncology

The approval’s significance extends beyond pancreatic cancer. Several drugmakers have invested heavily in KRAS-targeted approaches, but most have targeted specific KRAS subtypes or required covalent binding to a single mutation variant. The molecular glue strategy’s ability to hit multiple KRAS subtypes simultaneously could accelerate development timelines for competitors and set a new standard for target coverage.

Downstream trials across tumor types are expected. Kasi noted that “a lot more trials” are likely to follow, testing whether the approach works in colorectal, lung, and other cancers driven by KRAS mutations.

The pan-KRAS targeting capability distinguishes daraxonrasib from earlier KRAS inhibitors like sotorasib and adagrasib, which only target the G12C mutation found in approximately 3 percent of pancreatic cancers. While those drugs represented important progress for lung cancer patients, their narrow applicability left pancreatic cancer largely untouched.

Revolution Medicines has indicated that the molecular glue platform is being explored against additional oncology targets beyond KRAS, potentially expanding the therapeutic scope of this approach well beyond the current indication.

What Comes Next

The FDA’s accelerated approval is based on overall survival data, which is generally sufficient for regulatory action. However, full approval may require confirmatory trials demonstrating clinical benefit in broader patient populations.

Revolution Medicines will begin commercializing Rasonque in the coming months. Pricing, insurance coverage, and patient access programs remain unresolved details that will determine how quickly the drug reaches the patients who need it most.

The company has stated that it is working to establish equitable access frameworks, but the high cost typical of novel targeted therapies raises concerns about availability for uninsured and underinsured patients. Specialty pharmacy distribution and prior authorization processes will likely create initial access barriers that take time to navigate.

For now, the approval represents a rare bright spot in pancreatic cancer — a disease that has resisted nearly every therapeutic advance offered to other malignancies. The fact that a drug can nearly double survival in an already progressed population suggests that the KRAS target, long considered the holy grail of oncology drug discovery, may finally have yielded a genuine prize.

The scientific community is already looking ahead to the next frontier: combining daraxonrasib with immunotherapy and other targeted agents to push survival gains even further. Early preclinical studies suggest that pairing KRAS degradation with immune checkpoint blockade may produce synergistic effects, potentially transforming pancreatic cancer into a more treatable disease altogether.